METHOD FOR ESTIMATING CLINICAL EFFECTIVENESS OF HUMAN BLADDER CANCER BY REAL-TIME PCR AND KIT FOR IMPLEMENTATION THEREOF Russian patent published in 2012 - IPC C12Q1/68 C07H21/00 C12Q1/00 G01N33/53 

FIELD: medicine.

SUBSTANCE: invention refers to a method for estimating clinical effectiveness of human bladder cancer by real-time PCR and to a kit for implementation thereof. The presented invention may be used in medicine. The method involves patient's urine and blood sampling. RNA is recovered, cDNA is synthesised on an RNA matrix. The cDNA ATP6V1C1 concentration is rated in a reference gene. It is followed by quantitative PCR amplification of an ATP6V1C1 gene fragment. The clinical effectiveness is estimated by quantification of the amplified fragment of cDNA ATP6V1C1 for a sampled biomaterial; the clinical effectiveness is shown by decrease of the post-therapeutic urine and/or blood mRNA level of the ATP6V1C1 gene in 3 times and more as compared to the pre-therapeutic urine and/or blood mRNA level. A kit to be used in the method for estimating the clinical effectiveness of bladder cancer by real-time PCR includes primers with the sequence SEQ ID NO: 1 and 2 with molar ratio 1:1.

EFFECT: invention enables high-reliability diagnosing of bladder cancer, including at the early stage of progressing neoplastic aberration.

2 cl, 4 dwg, 4 tbl, 5 ex